Exposure to artemether-lumefantrine (Coartem®) in first trimester pregnancy in an observational study in Zambia

BACKGROUND: In general, safety data following exposure to drugs in the first trimester of pregnancy are scarce. More specifically, data on the safety of artemisinin-based combination therapy (ACT) in pregnancy still remain limited. Therefore, pregnant women from Choma, Zambia, who were exposed to ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Manyando, Christine, Njunju, Eric M, Virtanen, Mailis, Hamed, Kamal, Gomes, Melba, Van geertruyden, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336694/
https://www.ncbi.nlm.nih.gov/pubmed/25877884
http://dx.doi.org/10.1186/s12936-015-0578-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336694/
https://www.ncbi.nlm.nih.gov/pubmed/25877884
http://dx.doi.org/10.1186/s12936-015-0578-6

Ejemplares similares